# GILD · SCHEDULE 13G

- Kind: Filing note
- Ticker: GILD
- Company: GILEAD SCIENCES, INC.
- Form: SCHEDULE 13G
- Filed: 2026-11-06
- Accession: 0001123292-26-001496
- Canonical: https://edgartracker.com/s/GILD/2026-11-06/LoLQVDkTDuxORMfoOL-eew
- Updated: 2026-11-06T23:03:51.839496Z

---

# Aspen Neuroscience — Gilead Reports 2,879,996 Shares, or 9.9%; Position Value Undisclosed

## Filing Summary
Gilead Sciences, Inc. reports beneficial ownership of 2,879,996 Aspen Neuroscience shares, equal to 9.9% of the class, with sole voting and dispositive power. This establishes Gilead as a substantial minority holder, but the filing gives no prior Aspen-specific share count, so it does not show whether the position changed.

## Terms & Mechanics
- The reported event date is October 30, 2026; Gilead signed the filing on November 5, 2026.
- Gilead reports no shared voting or dispositive power and certifies that the securities are not held to influence or change control, subject to the filing’s stated exception for certain nomination-related activity.
- Acquisition history, purchase price, cost basis, transaction counterparties, and the position’s market value are not disclosed in filing materials. No related commercial or strategic agreement is disclosed.
- No prior Gilead filing concerning Aspen Neuroscience is supplied, so the change in shares or ownership percentage is not disclosed. The other context filings concern different issuers or reporting persons and do not establish a baseline.

## Strategic & Capital Implications
The 9.9% stake is a meaningful ownership position, but the passive-investment certification does not indicate a disclosed control effort. The filing alone does not establish a partnership or provide evidence of a financing commitment to Aspen.

The position’s financial significance to Gilead cannot be assessed without a disclosed price, cost basis, or accounting treatment. For Aspen, the reported percentage may change if its share count or Gilead’s holdings change; the filing does not disclose any associated dilution, capital-raising terms, or governance arrangement.

## Next Catalysts
- Any subsequent ownership filing reporting a change in Gilead’s share count or percentage.
- Any separate disclosure by either company of a commercial, financing, or strategic relationship.
- Changes in Aspen’s share count that could affect Gilead’s reported ownership percentage.

[Generated on Edgar Tracker · edgartracker.com · AI summary · GPT 6 luna · selected parts]